Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D06MIQ
|
|||
Former ID |
DCL000887
|
|||
Drug Name |
MRE-0094
|
|||
Synonyms |
SCHEMBL13010610; MRE 0094
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Diabetic foot ulcer [ICD-11: BD54; ICD-9: 707] | Phase 2 | [1] | |
Company |
Aderis Pharmaceuticals Licensee; King Pharmaceuticals
|
|||
Structure |
Download2D MOL |
|||
Formula |
C18H20ClN5O5
|
|||
Canonical SMILES |
C1=CC(=CC=C1CCOC2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N)Cl
|
|||
InChI |
1S/C18H20ClN5O5/c19-10-3-1-9(2-4-10)5-6-28-18-22-15(20)12-16(23-18)24(8-21-12)17-14(27)13(26)11(7-25)29-17/h1-4,8,11,13-14,17,25-27H,5-7H2,(H2,20,22,23)/t11-,13-,14-,17-/m1/s1
|
|||
InChIKey |
WUCQGGOGHZRELS-LSCFUAHRSA-N
|
|||
CAS Number |
CAS 131865-88-8
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Adenosine A2a receptor (ADORA2A) | Target Info | Agonist | [1] |
KEGG Pathway | Rap1 signaling pathway | |||
Calcium signaling pathway | ||||
cAMP signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Vascular smooth muscle contraction | ||||
Parkinson's disease | ||||
Alcoholism | ||||
Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | |||
Pathway Interaction Database | HIF-2-alpha transcription factor network | |||
Reactome | NGF-independant TRKA activation | |||
Adenosine P1 receptors | ||||
G alpha (s) signalling events | ||||
Surfactant metabolism | ||||
WikiPathways | Nucleotide GPCRs | |||
Monoamine Transport | ||||
GPCRs, Class A Rhodopsin-like | ||||
NGF signalling via TRKA from the plasma membrane | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
GPCRs, Other |
References | Top | |||
---|---|---|---|---|
REF 1 | Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.